Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma

Future Journal of Pharmaceutical Sciences

Tapas Ghosh¹  Paromita Bhattacharjee¹  Kakali Bhadra¹  Sarita Sarkar² 

[1] Department of Zoology, University of Kalyani;Present Address: Division of Molecular Medicine, Bose Institute;

关键词: Harmalol;    Histology;    DEN;    CCl4;    HCC;    Apoptosis;   

DOI  :  10.1186/s43094-020-00045-x

来源: DOAJ

【 摘 要 】

Abstract Background Diethylnitrosamine (DEN) promoted by carbon tetrachloride (CCl4) forms DNA adducts inducing hepatocellular carcinoma (HCC). Plant alkaloid, harmalol, is being used as a therapeutic agent against HCC due to its accessibility and efficacy by apoptosis and inhibiting proliferation of cancer epithelial cells. Result Seven groups of Swiss albino mice were taken. Different stages of liver tissues and serum from various experimental groups were collected before and after harmalol treatment. The investigation was carried out by enzyme assay, bilirubin level in the blood, DNA, RNA, normal serum protein of liver tissue, and alpha-feto protein estimation of serum. Gross morphological assessment of liver, histological, and different apoptosis markers viz. p53, caspase3, and cytochrome C expression were analyzed by RT-PCR and Western blot. Harmalol (10 mg/kg B.W. per week, I.P.) for 9 weeks showed a significant reduction in hepatocellular foci, nodules, and carcinoma ultimately retaining the normal morphology. It further induces ROS-dependent apoptosis through mitochondrial cytochrome C release that induces p53 by caspase3 activation. Conclusion The investigation will eventually help to develop more effective chemotherapeutic drugs from the natural source.

【 授权许可】

Unknown